Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

Background Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 receptor, preferentially activating CD8+ T cells and natural killer cells, with minimal expansion of regulatory T cells, thereby mitigating the risk...

Full description

Saved in:
Bibliographic Details
Main Authors: Lucy Gilbert, Jameel Muzaffar, Vamsidhar Velcheti, Anna Spreafico, Emiliano Calvo, David F McDermott, Marc S Ernstoff, Valentina Boni, Karl D Lewis, Ira Winer, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Christoper J Hoimes, Seth D Rosen, Debora S Bruno, James F Strauss, Rita Dalal, Ulka N Vaishampayan, Quincy S Chu
Format: Article
Language:English
Published: BMJ Publishing Group 2024-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/11/e010143.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/11/e010143.full

Similar Items